GLP-1 frequently asked questions

Wegovy's list price is about $1,349/month without insurance. Novo Nordisk's direct cash-pay program (NovoCare) has offered the pen for around $499/month to people paying out of pocket, and commercially insured patients may pay $0-225/month with the savings card (as of 2026 — confirm current program terms).

It varies widely. Wegovy is FDA-approved for chronic weight management, but many commercial plans explicitly exclude weight-loss drugs, and historically Medicare did not cover medications for obesity alone (this is shifting now that Wegovy carries an added cardiovascular indication). Coverage often hinges on your specific plan's formulary and documented medical need.

Compounded semaglutide via telehealth ($150-300/month) is the lowest-cost route but is not FDA-approved as a finished product. Zepbound (tirzepatide) is the other leading on-label weight-loss drug and sometimes has a lower net cost via the manufacturer's self-pay vials. Saxenda is an older, daily option. We compare these and redirect to licensed providers — we sell nothing ourselves.

Their list prices are similar (~$1,300 vs ~$1,000/month), but the real out-of-pocket cost depends on coverage and programs. Because Wegovy is approved for weight management, some weight-focused patients get better coverage or access to its $499 cash program; Ozempic's savings card requires a diabetes diagnosis. Compare both against your own plan.

Zepbound's list price is about $1,059/month for autoinjector pens. Eli Lilly's direct self-pay program (LillyDirect) offers single-dose vials at roughly $349-499/month depending on strength, which is the cheapest brand route for cash-pay patients. Savings cards can lower the cost further for those with commercial insurance (as of 2026).

Coverage is inconsistent. Zepbound is FDA-approved for weight management (and now obstructive sleep apnea), but many plans exclude weight-loss drugs and Medicare coverage for obesity alone has been limited. The added sleep-apnea indication is expanding some coverage. Check your plan's formulary and consider Lilly's self-pay vials if you are uninsured.

Often, yes, on a cash basis: Lilly's self-pay vials (~$349-499/month) tend to undercut Wegovy's ~$499 cash program, and Zepbound (tirzepatide) also produced greater average weight loss in trials (~22% vs ~15%). The right choice still depends on your coverage, tolerance, and prescriber's judgment — compare both before deciding.

Ozempic's list price is about $969-998/month for the cash-pay pen without insurance or coupons (as of 2026). Commercially insured patients may pay as little as $25/month with the Novo Nordisk savings card; Medicare and Medicaid pricing differ. Because Ozempic is FDA-approved for type 2 diabetes (not weight loss), plans frequently deny coverage when it is prescribed off-label for weight, leaving patients facing the full list price.

There is no generic version — semaglutide is patent-protected in the U.S. into the early 2030s, so a single manufacturer (Novo Nordisk) sets the price. It is also a biologic peptide that is complex to make, demand far outstrips supply, and U.S. list prices are not negotiated the way they are in most other countries. These factors keep the cash price near $1,000/month.

Yes. Compounded semaglutide via telehealth runs roughly $150-300/month (same active ingredient, but not FDA-approved as a finished product). Rybelsus is an oral semaglutide from the same maker. For weight loss specifically, Wegovy and Zepbound are the on-label options. We do not sell any of these — compare the trade-offs and pricing on our drug pages, then we redirect you to a licensed provider.

Options include: the manufacturer savings card if you have commercial insurance, the NovoCare patient-assistance program if you are low-income and uninsured, cash-pay telehealth programs, asking your prescriber to submit a prior-authorization appeal, or considering lower-cost compounded semaglutide (with the regulatory caveats). Pharmacy price varies, so it is worth comparing.

Mounjaro's list price is about $1,069/month without insurance. Commercially insured patients with type 2 diabetes may pay as little as $25/month with the Eli Lilly savings card. Mounjaro is approved for diabetes, not weight loss — when prescribed off-label for weight, coverage is often denied, exposing the full price.

Like Ozempic, tirzepatide has no generic and a single manufacturer (Eli Lilly) holding patents into the 2030s. It is a dual GLP-1/GIP biologic that is costly to produce, demand is high, and U.S. list prices are unregulated. The result is a cash price above $1,000/month.

Compounded tirzepatide via telehealth ($200-450/month) is the cheapest option but is not FDA-approved as a finished product. Zepbound is the same molecule approved for weight loss and has lower-cost self-pay vials. Ozempic/Wegovy (semaglutide) are alternative-class choices. We list pricing and redirect to licensed providers rather than selling anything.

Rybelsus has a list price of approximately $998/month for 30 tablets, comparable to Ozempic. Manufacturer NovoCare savings cards can reduce commercially-insured copays significantly. Cash-pay prices vary by pharmacy. Rybelsus is FDA-approved only for type 2 diabetes; insurance coverage is generally consistent for that indication.

Rybelsus is not FDA-approved for weight loss. Average weight loss in PIONEER trials was 2.3-4.4 kg over 26 weeks — substantially less than injectable semaglutide (Wegovy averaged 14.9% in STEP-1). Off-label use exists, but for weight management specifically, Wegovy or Zepbound are the on-label FDA-approved choices.

Take Rybelsus on an empty stomach in the morning with no more than 4 ounces of plain water. Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Bioavailability is only 0.4-1% — strict timing is required for the absorption enhancer (SNAC) to work. Skipping the 30-minute rule can substantially reduce drug effect.

Both contain semaglutide. Rybelsus is the oral tablet form (3-14mg daily); Ozempic is the weekly subcutaneous injection (0.25-2mg). Same molecule, very different formulations and bioavailability profiles. Ozempic achieves higher systemic exposure and stronger A1C/weight effects; Rybelsus is needle-free but requires strict empty-stomach dosing daily.

Saxenda's list price is approximately $1,349/month — the same tier as Wegovy. NovoCare savings programs may reduce cost for commercially-insured patients. Cash-pay Saxenda is rarely a value choice in 2026 because Wegovy and Zepbound offer weekly dosing at comparable or lower cost. The exception: pediatric patients (Saxenda and Wegovy are the two GLP-1s approved for ages 12+).

No. Saxenda contains liraglutide (daily injection, 3mg); Wegovy contains semaglutide (weekly, 2.4mg). Both are FDA-approved for chronic weight management but use different active ingredients. Wegovy produced higher average weight loss in trials (14.9% in STEP-1 vs 7.4% in SCALE-Obesity for Saxenda). Saxenda predates Wegovy by 7 years and has largely been superseded for new patients.

Yes, Saxenda remains commercially available. The FDA resolved the Saxenda shortage in May 2024. Usage has declined sharply with the launches of Wegovy (2021) and Zepbound (2023). Saxenda remains relevant primarily for adolescents (ages 12+ approval) and patients who tolerate liraglutide better than semaglutide individually.

Yes, switching is straightforward. Saxenda (liraglutide) and Wegovy (semaglutide) are different molecules in the same drug class. Your prescriber typically discontinues Saxenda then initiates Wegovy at the standard 0.25mg starter dose, regardless of your Saxenda dose. Some patients tolerate the switch better with a 1-2 week washout; others transition immediately. Discuss with your prescriber.

Trulicity's list price is approximately $987/month. Eli Lilly's manufacturer savings card can reduce commercial-insurance copays. Trulicity is FDA-approved for type 2 diabetes only — insurance coverage is generally consistent for that indication. It is not FDA-approved for weight loss, though it produces ~3% average weight reduction at the 1.5mg dose in trials.

Head-to-head trials (SURPASS-2 + related) showed Mounjaro (tirzepatide) achieved greater A1C reduction and weight loss vs Trulicity (dulaglutide). Mounjaro is the dual GIP/GLP-1 agonist with higher potency. Trulicity is older but valued for its very simple auto-injector device and 12% cardiovascular event reduction shown in REWIND. Choice depends on your priorities: maximum potency (Mounjaro) vs simplicity + CV data (Trulicity).

Trulicity produces modest weight loss — average 3% body weight at the 1.5mg dose over 52 weeks in REWIND. This is lower than semaglutide-based or tirzepatide-based GLP-1s. Trulicity is FDA-approved for type 2 diabetes and cardiovascular event reduction in adults with T2D plus established CVD, not for weight loss specifically.

No — Novo Nordisk discontinued Victoza (liraglutide 1.2/1.8 mg for diabetes) in April 2024. Existing prescriptions may still be filled while pharmacy supply lasts, but no new manufacturing is occurring. Patients should discuss alternatives with their prescriber. Saxenda (liraglutide 3.0 mg, for weight management) remains available and uses the same active ingredient at a higher dose.

There is no direct generic-style replacement for Victoza. Novo Nordisk continues Saxenda (the higher-dose liraglutide for weight). For diabetes patients on Victoza, prescribers typically transition to Ozempic (weekly semaglutide), Trulicity (weekly dulaglutide), Mounjaro (weekly tirzepatide), or Rybelsus (oral semaglutide), based on clinical factors and insurance coverage.

Novo Nordisk did not publicly cite a specific reason for the April 2024 Victoza discontinuation. Industry observers note Victoza's 2010 approval put it among the older GLP-1s, with newer weekly options (Ozempic, Trulicity) capturing market share due to better adherence. Manufacturing capacity for liraglutide was likely reallocated to Saxenda and other priority products.

Compounded semaglutide uses the same active ingredient (semaglutide) as Ozempic, so the pharmacological effect is expected to be similar. The difference is regulatory: Ozempic is FDA-approved as a finished product with full manufacturing oversight, while compounded versions are NOT FDA-reviewed for safety, potency, or quality. Efficacy can vary by compounding pharmacy.

Compounded semaglutide from a state-licensed 503A pharmacy or 503B outsourcing facility, prescribed by a licensed clinician, is legal. However, the FDA has warned about fraudulent online sellers, mislabeled products, and unapproved "salt" forms (semaglutide sodium). Legitimacy depends on the specific pharmacy — verify accreditation and require a real prescription.

Availability is shrinking. After the FDA declared the semaglutide shortage resolved, the legal basis for mass-compounding narrowed, and the FDA has moved to permanently restrict compounded GLP-1s. Some 503A pharmacies still produce personalized formulations (e.g. with B12), but broad availability is being phased out as commercial supply stabilizes. Check current status with your provider.

Tirzepatide (the molecule in Mounjaro/Zepbound) produced greater average weight loss than semaglutide in head-to-head trials (~22% vs ~15%). Compounded tirzepatide therefore tends to deliver stronger results, but may cause more GI side effects and faces the same regulatory phase-out as compounded semaglutide.

Most patients lose roughly 1-2 pounds per week on semaglutide once titrated to an effective dose, so a 20-pound loss is typically achievable in about 10-16 weeks when paired with diet and activity. Higher starting weights often see faster early loss. Individual results vary widely.

Compounded semaglutide via telehealth typically runs $150-300/month cash-pay (some as low as ~$70-129 on intro pricing), versus $1,000-1,865/month list for FDA-approved Ozempic or Wegovy without insurance. The lower cost is the main reason patients choose compounded — weighed against reduced regulatory oversight.

Compounded tirzepatide uses the same active ingredient as Mounjaro and Zepbound, so the expected effect is similar. The distinction is regulatory: brand tirzepatide is FDA-approved with full oversight; compounded versions are not FDA-reviewed for safety, potency, or quality. Results can vary by compounding pharmacy.

Compounded tirzepatide from a licensed 503A/503B pharmacy with a valid prescription is legal, but the FDA has flagged fraudulent sellers and mislabeled products. Legitimacy depends on the specific pharmacy — verify accreditation and insist on a clinician prescription.

Like compounded semaglutide, availability is tightening. As tirzepatide comes off the FDA shortage list, the legal basis for compounding narrows and the FDA is restricting compounded GLP-1s. Some personalized formulations remain; broad availability is being phased out. Confirm current status with your provider.

Compounded tirzepatide via telehealth typically runs $200-450/month cash-pay, versus ~$1,000+/month list for brand Mounjaro or Zepbound without insurance. The cost savings drive demand, balanced against the regulatory trade-off.